Wormsley S B, Rai K R, Gale R P
Cytometrics Division, Specialty Laboratories, San Diego, CA 92121.
Nouv Rev Fr Hematol (1978). 1988;30(5-6):413-7.
As therapeutic protocols to treat chronic lymphocytic leukemia evolve, new criteria will be required to define remission and identify early relapse. Two techniques that detect low numbers of residual monoclonal B-lymphocytes currently include immunoglobulin (Ig) gene rearrangement and clonal excess analysis. Ig-gene rearrangement studies are time consuming and expensive. Clonal excess analysis by FC may be insensitive because of minimal surface immunoglobulin (SIg) expression. Three antigens, CD5, CD11c and CD14 are expressed on B-lymphocytes of CLL. CD14 is also expressed on most normal B-lymphocytes. In contrast, CD5 and CD11c are expressed on few normal B-lymphocytes. Consequently CD5 and CD11c are useful markers for detecting residual CLL cells. Appropriate selection of the second B-cell marker such as SIg, CD19, CD20 or other, is critical. We evaluated this approach in persons with CLL receiving therapy. Preliminary results will be presented.
随着治疗慢性淋巴细胞白血病的治疗方案不断发展，将需要新的标准来定义缓解情况并识别早期复发。目前，检测少量残留单克隆B淋巴细胞的两种技术包括免疫球蛋白（Ig）基因重排和克隆过剩分析。Ig基因重排研究耗时且昂贵。由于表面免疫球蛋白（SIg）表达极少，通过流式细胞术进行的克隆过剩分析可能不敏感。三种抗原，即CD5、CD11c和CD14在慢性淋巴细胞白血病的B淋巴细胞上表达。CD14在大多数正常B淋巴细胞上也有表达。相比之下，CD5和CD11c在很少的正常B淋巴细胞上表达。因此，CD5和CD11c是检测残留慢性淋巴细胞白血病细胞的有用标志物。正确选择第二种B细胞标志物，如SIg、CD19、CD20或其他标志物至关重要。我们在接受治疗的慢性淋巴细胞白血病患者中评估了这种方法。将展示初步结果。
